Kinnate Biopharma Inc.
KNTENASDAQHealthcare
$2.65
$-0.01(-0.38%)
Market Cap$124990960
P/E Ratio—
52W High$7.185
52W Low$1.04
Kinnate Biopharma Inc. (KNTE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KNTE · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 9, 2024EPS Actual
-$0.73
Est. -$0.34 · -114.7%
Revenue
—
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 9, 2024
After Market Close
▼ Miss EPS
KNTE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 9, 2024 | -$0.34 | -$0.73 | -114.7% | — | — | — |
| ▲ Q1 FY2024 | Mar 27, 2024 | -$0.42 | -$0.36 | +14.3% | — | — | — |
| ▲ Q4 FY2023 | Nov 9, 2023 | -$0.69 | -$0.65 | +5.8% | — | — | — |
| ▲ Q3 FY2023 | Aug 8, 2023 | -$0.76 | -$0.68 | +10.5% | — | — | — |
| — Q2 FY2023 | May 11, 2023 | -$0.73 | -$0.73 | +0.0% | — | — | — |
| ▼ Q1 FY2023 | Mar 15, 2023 | -$0.70 | -$0.72 | -2.9% | — | — | — |
| ▼ Q4 FY2022 | Nov 10, 2022 | -$0.60 | -$0.70 | -16.7% | — | — | — |
| ▲ Q3 FY2022 | Aug 11, 2022 | -$0.65 | -$0.62 | +4.6% | — | — | — |
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.73
EPS Est.
-$0.34
EPS Surpr.
-114.7%
Revenue
—
Q1 FY2024
Mar 27, 2024Beat
EPS Actual
-$0.36
EPS Est.
-$0.42
EPS Surpr.
+14.3%
Revenue
—
Q4 FY2023
Nov 9, 2023Beat
EPS Actual
-$0.65
EPS Est.
-$0.69
EPS Surpr.
+5.8%
Revenue
—
Q3 FY2023
Aug 8, 2023Beat
EPS Actual
-$0.68
EPS Est.
-$0.76
EPS Surpr.
+10.5%
Revenue
—
Q2 FY2023
May 11, 2023
EPS Actual
-$0.73
EPS Est.
-$0.73
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2023
Mar 15, 2023Miss
EPS Actual
-$0.72
EPS Est.
-$0.70
EPS Surpr.
-2.9%
Revenue
—
Q4 FY2022
Nov 10, 2022Miss
EPS Actual
-$0.70
EPS Est.
-$0.60
EPS Surpr.
-16.7%
Revenue
—
Q3 FY2022
Aug 11, 2022Beat
EPS Actual
-$0.62
EPS Est.
-$0.65
EPS Surpr.
+4.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q3 FY2025 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q2 FY2025 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q1 FY2025 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q4 FY2024 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2024 | $-0.29 | $-0.29 | $-0.29 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 9, 2024 | -114.7% | $2.65 | — | — |
| ▲ Q1 FY2024 | Mar 27, 2024 | +14.3% | $2.63 | $2.66 | +1.14% |
| ▲ Q4 FY2023 | Nov 9, 2023 | +5.8% | $1.21 | $1.20 | -0.83% |
| ▲ Q3 FY2023 | Aug 8, 2023 | +10.5% | $2.79 | $2.64 | -5.38% |
| ▲ Q2 FY2023 | May 11, 2023 | +0.0% | $3.48 | $3.58 | +2.87% |
| ▼ Q1 FY2023 | Mar 15, 2023 | -2.9% | $4.49 | $4.67 | +4.01% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -16.7% | $8.43 | $8.81 | +4.51% |
| ▲ Q3 FY2022 | Aug 11, 2022 | +4.6% | $14.82 | $13.33 | -10.05% |
Q2 FY2024—
Report Date
May 9, 2024
EPS Beat/Miss
-114.7%
Price Before
$2.65
Price After
—
Q1 FY2024+1.14%
Report Date
Mar 27, 2024
EPS Beat/Miss
+14.3%
Price Before
$2.63
Price After
$2.66
Q4 FY2023-0.83%
Report Date
Nov 9, 2023
EPS Beat/Miss
+5.8%
Price Before
$1.21
Price After
$1.20
Q3 FY2023-5.38%
Report Date
Aug 8, 2023
EPS Beat/Miss
+10.5%
Price Before
$2.79
Price After
$2.64
Q2 FY2023+2.87%
Report Date
May 11, 2023
EPS Beat/Miss
+0.0%
Price Before
$3.48
Price After
$3.58
Q1 FY2023+4.01%
Report Date
Mar 15, 2023
EPS Beat/Miss
-2.9%
Price Before
$4.49
Price After
$4.67
Q4 FY2022+4.51%
Report Date
Nov 10, 2022
EPS Beat/Miss
-16.7%
Price Before
$8.43
Price After
$8.81
Q3 FY2022-10.05%
Report Date
Aug 11, 2022
EPS Beat/Miss
+4.6%
Price Before
$14.82
Price After
$13.33
Avg Beat Reaction-2.45%
Avg Miss Reaction+4.26%
Beat Rate5 / 8 quarters
Largest Move-10.05% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KNTE ends December
Kinnate Biopharma Inc. (KNTE) most recently reported earnings on May 9, 2024 for Q2 FY2024, posting EPS of $-0.73 — missing the analyst consensus of $-0.34 by -114.7%. The next KNTE earnings date is expected around September 1, 2026.
Each quarter, investors track KNTE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KNTE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KNTE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KNTE earnings · 5 questionsKinnate Biopharma Inc.'s next earnings report is expected around September 1, 2026. KNTE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KNTE historically reports after market close (AMC).
KNTE earnings datewhen is KNTE earningsKNTE next earnings datewhen does KNTE report earningsKNTE earnings calendar
▸ Source: FMP · Kinnate Biopharma Inc. SEC filings · US GAAP · Kinnate Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026